Clinical Report: Video: Sitting Down With… John Tomtishen

Overview

In an interview produced in partnership with IBTV, John Tomtishen, Catalent’s Global Head of Cell Therapy Field Application Scientists and Strategic Alliances, discusses his career and changes in the cell therapy field. He emphasizes prioritizing product characterization and chemistry, manufacturing, and controls (CMC) early in development, and discusses technologies and manufacturing strategies related to scalability.

Background

Cell therapy development involves product characterization and CMC considerations, which Tomtishen identifies as priorities early in development. The interview also addresses technologies and manufacturing strategies that could improve scalability. The source describes these topics in the context of changes Tomtishen has witnessed across the field. It does not provide trial results or quantitative clinical data.

Data Highlights

The source is a video interview and reports no numerical or trial data.

Key Findings

• John Tomtishen is identified as Global Head of Cell Therapy Field Application Scientists and Strategic Alliances at Catalent.
• The interview covers his career and changes he has observed in the cell therapy field.
• Tomtishen explains why developers should prioritize product characterization early in development.
• He also emphasizes early attention to CMC.
• The discussion explores technologies and manufacturing strategies that could improve scalability.
• Tomtishen shares his perspective on what the industry must do to bring the next generation of transformative cell therapies to more patients.

Clinical Implications

The interview highlights early product characterization and CMC as development priorities, alongside consideration of technologies and manufacturing strategies related to scalability. These points are presented as Tomtishen’s perspective; the source does not provide specific clinical recommendations or comparative evidence.

Conclusion

The interview focuses on development and manufacturing considerations in cell therapy, particularly early product characterization and CMC and strategies for scalability. It presents Tomtishen’s perspective on the field and on expanding access to future therapies.

Related Resources & Content

1. The Analytical Scientist — Nanotech Titan: Part One
2. inside dental technology — Take Your Seat at the Table
3. The Analytical Scientist — Video: Sitting down with Fasha Mahjoor
4. the analytical scientist — Tea With… Grace
5. Chemistry, Manufacturing, and Controls Flexibilities for Developing Human Cellular and Gene Therapy Products for a Biologics License Application | FDA
6. Long-term survivorship rates among previously treated advanced melanoma patients achieving objective response (OR) with lifileucel. | Journal of Clinical Oncology
7. ASTCT Grading for Toxicities After Immune Effector Cell Therapy Guideline Summary - Guideline Central